# Agile Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agile-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Princeton, US
- Website: www.agiletherapeutics.com
- Total disclosed funding: $65M
- Latest round: Series C (Jul 18, 2012)
- Investors on record: 8

## About

Agile Therapeutics Inc. is a US-based company dedicated to developing innovative healthcare solutions for women, particularly focusing on contraceptive products that enhance the delivery of hormones through advanced technology.Agile Therapeutics Inc. is a healthcare company that specializes in developing contraceptive products for women. Founded in 1997 and headquartered in Princeton, New Jersey, US, the company has executed a total of 16 deals in its history. Al Altomari serves as the current CEO. In July 2022, Agile Therapeutics raised USD 24.00 mn in a Private Placement/Follow on, which coincides with the total amount raised by the company.Agile Therapeutics specializes in developing innovative healthcare solutions for women, particularly in contraceptive products. Their flagship product, Twirla®, is a transdermal contraceptive patch incorporating proprietary SkinFusion® Technology to effectively deliver hormones through the skin, providing a reliable and convenient birth control option for women of reproductive age in the US. The company is committed to expanding its product pipeline to meet the evolving needs of its clientele.In 2023, Agile Therapeutics reported a revenue of USD 19.59 mn, with an EBITDA of USD -19.50 mn. The company's revenue primarily comes from the sale of Twirla®, using a direct-to-consumer sales approach in collaboration with healthcare providers and pharmacies to ensure accessibility of their contraceptive solutions.Agile Therapeutics plans to leverage recent funding to support pre-launch activities for its new product AG200-15, along with the continued development of AG890, a progestin-only contraceptive patch. The company aims to expand its market presence and reach specific geographic regions by targeting new markets for its innovative contraceptive solutions.

## Funding rounds

- Series C, Jul 18, 2012, $24M — Care Capital, Novitas Capital, Aisling Capital, Patricia Industries, ProQuest Investments, Kaiser Permanente Ventures
- Series E, May 25, 2010, $24M — Care Capital, Novitas Capital, Patricia Industries, ProQuest Investments, Kaiser Permanente Ventures
- Series E, Dec 20, 2007, $5M — Novitas Capital, TL Ventures, Hillman Company, ProQuest Investments
- Series E, May 25, 2006, $12M — Novitas Capital, TL Ventures, Hillman Company, ProQuest Investments

## Investors

- Novitas Capital (https://capitalatlas.ai/funds/novitas-capital) — Series E, Series C
- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series E
- Hillman Company — Series E
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series E, Series C
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series E, Series C
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series E, Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series E, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C